EMA Authorised: Besponsa (Inotuzumab ozogamicin) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Besponsa (inotuzumab ozogamicin) for precursor cell lymphoblastic leukemia-lymphoma under Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: Pfizer Europe MA EEIG. Decision date: 11/09/2025. Orphan medicine